TY  - GEN
AU  - Yang,Sheng-Hsiang
AU  - Hsiao,Liang-Tsai
AU  - Chiou,Tzeon-Jye
AU  - Yang,Ching-Fen
AU  - Yu,Yuan-Bin
AU  - Liu,Chun-Yu
AU  - Gau,Jyh-Pyng
AU  - Liu,Jin-Hwang
AU  - Chen,Po-Min
AU  - Tzeng,Cheng-Hwai
TI  - Rituximab induction therapy, survival benefits, and the increasing selection of radiotherapy as the postinduction treatment in patients with primary mediastinal large B-cell lymphoma
SN  - 1728-7731
PY  - 2017///0104
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents
KW  - therapeutic use
KW  - Combined Modality Therapy
KW  - Female
KW  - Fluorodeoxyglucose F18
KW  - Humans
KW  - Induction Chemotherapy
KW  - Lymphoma, Large B-Cell, Diffuse
KW  - mortality
KW  - Male
KW  - Mediastinal Neoplasms
KW  - Middle Aged
KW  - Positron-Emission Tomography
KW  - Rituximab
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.jcma.2015.02.005
ER  -